期刊
CLINICA CHIMICA ACTA
卷 411, 期 23-24, 页码 1957-1962出版社
ELSEVIER
DOI: 10.1016/j.cca.2010.08.014
关键词
Imatinib; Human plasma; Mass spectrometry; Flow injection analysis; Liquid chromatography; Therapeutic drug monitoring
资金
- Ministry of Health [IGA MZCR NS9627]
- Ministry of Education, Youth and Sports [MSM 6198959205]
- Iceland, Liechtenstein
- Norway through the EEA [A/CZ0046/2/0011]
Background: The aim of this study was to develop, validate and compare flow injection analysis (FIA) and ultra-high-performance liquid chromatography (LC)/tandem mass spectrometry methods for the determination of imatinib in plasma from patients with chronic myeloid leukemia. Methods: The plasma for analysis by both methods was deproteinated by methanol containing d8-imatinib. The separation was achieved on a 1.7 mu m C18 column with a linear gradient (4 mM ammonium formiate and acetonitrile, pH 3.2). FIA was performed at flow rate of 0.03 mL/min (0.1% formic acid in methanol). Multiple reaction monitoring mode on the tandem mass spectrometer (API 4000, AB Sciex) in positive ESI were used for detection. Results: The total analysis times were 3.2 (LC) and 0.75 min (FIA). Both methods were successfully validated and applied to the plasma patients samples. The limits of quantification were 4.1 and 30.8 ng/mL; imprecisions were less than 5.7% and recovery ranged between 93 and 105%, for the LC and FIA, respectively. The methods revealed an agreement with a mean difference of 1.46 ng/mL (SD 28.95 ng/mL). Conclusions: The high-throughput methods that were developed are suitable for the therapeutic drug monitoring of imatinib in plasma. They can be used in routine clinical practice. (C) 2010 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据